ArticleTherapeutic advances in gastroenterology2025
Vonoprazan-minocycline dual therapy as a first-line treatment of
Article in Therapeutic advances in gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Comparative efficacy, safety and compliance with dual, triple and quadruple therapy as the first-line treatment regimens forBMJ open gastroenterology · 2026Pooled it
- Efficacy and safety of antibiotic regimens forFrontiers in medicine · 2026Pooled it
- Trial
- Fourteen-Day Vonoprazan-Minocycline vs Vonoprazan-Amoxicillin Dual Therapy for Primary Helicobacter pylori Infection: A Propensity Score Matching Analysis.Clinical and translational gastroenterology · 2026Article
- Minocycline-containing therapy inTherapeutic advances in gastroenterology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Increasing antibiotic resistance compromises therapeutic options for Objectives: This trial aimed to assess the efficacy and safety of 14-day vonoprazan-minocycline (VM) dual therapy against bismuth-containing quadruple therapy (B-quadruple therapy), as initial treatment for Design: This study was a single-center, open-label, and non-inferiority randomized controlled trial. Methods: In this study, 240 individuals with Results: The eradication rates of VM dual group and B-quadruple therapy group were 87.5% and 88.3%, respectively, by intention-to-treat (ITT) analysis; 92.1% and 94.6% by modified ITT (mITT) analysis; and 92.0% and 95.5% by per-protocol (PP) analysis. The eradication rates of the VM group were non-inferior to those of the B-quadruple therapy group in ITT, mITT, and PP analyses (one-sided Conclusion: The VM dual therapy was not inferior to the B-quadruple therapy in the initial treatment of Trial registration: This trial was registered on the Chinese Clinical Trial Registry with the registration number ChiCTR2400081461.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.